MicrobiotiX Expands Global Reach with African Collaboration on Bacteriophage Therapies

New updates have been reported about MicrobiotiX (PC:MICRO)

MicrobiotiX has taken a significant step in its strategic expansion by signing a memorandum of understanding with the West Africa Centre for Innovative Research and Care (WAFCIRC) and Komfo Anokye Teaching Hospital in Ghana. This collaboration focuses on the clinical research of bacteriophage-based therapies aimed at combating antimicrobial resistance (AMR) and multidrug-resistant (MDR) bacteria. The partnership will facilitate the clinical validation of these novel therapeutics, particularly in African regions where access to antibiotics is limited. MicrobiotiX will supply its bacteriophage candidates from its GMP facility and provide funding and technical support for the research.

This initiative is part of MicrobiotiX’s broader strategy to address global health challenges, starting with Ghana and potentially expanding across Africa. The collaboration is expected to enhance infectious disease preparedness and response in vulnerable regions. A representative from MicrobiotiX emphasized the importance of this partnership as a step toward alleviating unmet medical needs in low- and middle-income countries while contributing to global efforts against AMR and MDR. Additionally, MicrobiotiX is advancing its lead pipeline candidate, a bacteriophage therapeutic for acute Pseudomonas aeruginosa pneumonia, which recently received approval for a Phase 1 human clinical trial from the Korean Ministry of Food and Drug Safety. This development underscores MicrobiotiX’s commitment to innovation and its proactive approach in addressing critical health issues.